Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

48.23 +1.14 (+2.42%)

Streaming Delayed Price Updated: 10:46 AM EDT, Mar 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

35 36 Next >

3 Healthcare Stocks That Could Go Parabolic ↗

November 09, 2022

These beaten-down stocks are ready for a rebound.

Via The Motley Fool

Why Shares of CRISPR Therapeutics Dropped 19.9% in October ↗

November 07, 2022

Several factors weighed on the gene-editing biotech stocks last month.

Via The Motley Fool

Got $1,000? 2 Smart Stocks to Consider Buying Right Now ↗

November 06, 2022

Don't overlook these major healthcare names on your next stock-buying spree.

Via The Motley Fool

2 Biotech Stocks That Could Make You Richer ↗

November 04, 2022

Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.

Via The Motley Fool

3 Top Healthcare Stocks to Buy for November ↗

November 04, 2022

Catalysts lie ahead for these promising stocks.

Via The Motley Fool

Where CRISPR Therapeutics Stands With Analysts ↗

November 02, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:

Via Benzinga

What 8 Analyst Ratings Have To Say About CRISPR Therapeutics ↗

November 02, 2022

Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings:

Via Benzinga

Expert Ratings for CRISPR Therapeutics ↗

November 02, 2022

Over the past 3 months, 8 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Better Buy: CRISPR Therapeutics vs. Bluebird Bio ↗

October 27, 2022

These two companies have performed almost equally poorly on the stock market in the past year.

Via The Motley Fool

2 Monster Stocks to Buy Without Any Hesitation ↗

October 26, 2022

These stocks are crushing the bear market.

Via The Motley Fool

Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗

October 24, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.48% on an annualized basis producing an average annual return of 21.37%. Currently, CRISPR Therapeutics has a...

Via Benzinga

S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength ↗

October 22, 2022

Vertex and LNG play Cheniere Energy are setting up bullishly.

Via Investor's Business Daily

The Top 5 Stocks Cathie Wood Bought and Sold This Week ↗

October 21, 2022

Cathie Wood's flagship ETF, the ARK Innovation ETF, hit a five-year and 52-week low this week, casting doubts on the investment manager.

Via InvestorPlace

2 Budding Growth Stocks That Could Turn $1,000 Into $10,000 in 8 Years ↗

October 21, 2022

They're both using unique and highly efficient approaches to developing and deploying their medicines.

Via The Motley Fool

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗

October 20, 2022

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Via Investor's Business Daily

2 Under-the-Radar Biotech Stocks to Buy in 2022 ↗

October 19, 2022

These two drugmakers are growing in prominence.

Via The Motley Fool

3 Cathie Wood Stocks to Buy and Hold for 10 Years ↗

October 19, 2022

The risks are formidable, but the chances of a massive gain are too much to pass up.

Via The Motley Fool

2 Top Healthcare Stocks to Buy for the Long Haul ↗

October 18, 2022

These biotech companies have a long ramp of revenue growth ahead.

Via The Motley Fool

My Best Stocks to Buy Now and Hold Forever ↗

October 14, 2022

These are ideal "forever" stocks.

Via The Motley Fool

Missed Out On Axsome Therapeutics? My Best Biotech Stock to Buy and Hold ↗

October 12, 2022

Vertex already generates billions in revenue -- but there may be more to come.

Via The Motley Fool

What 7 Analyst Ratings Have To Say About CRISPR Therapeutics ↗

October 11, 2022

Analysts have provided the following ratings for CRISPR Therapeutics (NASDAQ:CRSP) within the last quarter:

Via Benzinga

These 7 Biotech Stocks Are Set to Boom in 2023 ↗

October 10, 2022

This article looks at seven biotech stocks that look like good options to move significantly higher in 2023

Via InvestorPlace

2 Cathie Wood Stocks That Are Beating the Market This Year ↗

October 07, 2022

One is doing much better than the other year to date, but they both have solid prospects ahead.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗

October 11, 2022

Upgrades

Via Benzinga

Vertex Shares Higher On Optimism About CRISPR Partnership

October 05, 2022

Shares of Vertex Pharmaceuticals are moving higher on news that regulators gave the company the go-ahead to on the review process for gene-editing treatments.

Via MarketBeat

Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future ↗

October 03, 2022

Bluebird Bio Inc (NASDAQ: BLUE) is about to become the seller of the two most expensive drugs in the U.S. and probably the world. The price tag of $3 million is already facing backlash.

Via Benzinga

Vertex, Gene-Editing Leader, Heads 5 Resilient Stocks In Bear Market ↗

October 01, 2022

Vertex flashed a buy signal on positive gene-editing news.

Via Investor's Business Daily

Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review ↗

September 30, 2022

The major indexes fell, with the S&P 500 breaking below bear market lows.

Via Investor's Business Daily

MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders ↗

September 28, 2022

MaxCyte Inc (NASDAQ: MXCT) has signed a

Via Benzinga

What Is Going on With Grom Social (GROM) Stock Today? ↗

September 27, 2022

Grom Social (GROM) stock is heading higher on Tuesday following news of Chelsea and Matt Giegerich signing a deal with Curiosity Ink Media.

Via InvestorPlace

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.